Zingiberen newsaponin

Zingiberen Newsaponin (Zingiberensis newsaponin) is an orally active type of steroid saponin compound. Zingiberen Newsaponin exerts anti-hepatocellular carcinoma (HCC) effects by inhibiting autophagy and the AKR1C1/JAK2/STAT3 pathway. Zingiberen Newsaponin activates oxidative stress (upregulates ROS and MDA) and mitochondrial pathways, promoting cancer cell apoptosis. Zingiberen Newsaponin alleviates cerebral ischemia-reperfusion (I/R) injury by decreasing the concentration of pro-inflammatory cytokines and inhibits NF-κB. Zingiberen Newsaponin can enhance the activity of SOD, eliminate free radicals and protect nerve cells. Zingiberen Newsaponin induces platelet aggregation^[1][2][3]. In Vitro:Zingiberen Newsaponin (0-2 μM, 48 h) inhibits proliferation of Huh7 and SMMC-7721 cells, with IC₅₀ values of 443.8 nM and 841.8 nM^[2].
Zingiberen Newsaponin (0.5-1 μM, 24-48 h) significantly inhibits the migration of Huh7 and SMMC-7721 cells and induces cell apoptosis^[2].
Zingiberen Newsaponin (0.5-1 μM, 48 h) inhibits AKR1C1/JAK2/STAT3 signaling pathway, induces oxidative stress and inhibits autophagy in Huh7 and SMMC-7721 cells^[2].
Zingiberen Newsaponin (48 h) significantly reduces the secretion of pro-inflammatory cytokines TNF-α and IL-6 and downregulates NF-κB protein expression in LPS (HY-D1056)-stimulated RAW264.7 cells^[3].
Zingiberen Newsaponin (48 h) significantly improves PC12 cell survival and reduces apoptosis in an ischemia-reperfusion (I/R) cell model^[3].
In Vivo:Zingiberen Newsaponin (60 mg/kg, p.o., once daily for 28 days) significantly inhibits tumor growth in a mouse HCC xenograft model^[2].
Zingiberen Newsaponin (i.g., once daily for 7 days or single dose) significantly improves cerebral I/R injury, reducing infarct size and neurological deficits in rats^[3].